OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
22
Results
Show all
Save search
Copy query
Show results for
Unknown
(18)
Genomics
(3)
Transcriptomics
(1)
Organisms
Homo sapiens
(3)
Mus musculus
(1)
Repository
EGA
(3)
biostudies-arrayexpress
(1)
Technology Type
Infinium Omni2.5M
(1)
Publication Date
2010
(1)
Study type
Transcription profiling by array
(1)
Release Date
2025
(7)
2024
(2)
2023
(2)
2010
(1)
2022
(1)
2021
(1)
2019
(1)
2016
(1)
2013
(1)
2012
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Not available
S-EPMC5321098
|
biostudies-literature
Cite
Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder.
Not available
S-EPMC9138236
|
biostudies-literature
Cite
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.
Not available
S-EPMC12221278
|
biostudies-literature
Cite
Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder.
Not available
S-EPMC9866623
|
biostudies-literature
Cite
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Not available
S-EPMC12353800
|
biostudies-literature
Cite
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.
Not available
S-EPMC12639436
|
biostudies-literature
Cite
Infinium Omni2.5
Case control samples using Infinium Omni2.5
EGAD00010001198
|
EGA
Cite
GWAS data (Illumina 2.5 M SNPs) in Cuban cohorts of dengue disease
We will have 274 individuals typed for the Illumina Human Omni 2.5 chip. The individuals are from two locations in Cuba (Havana and Guantanamo) and from four phenotype classes (asymptomatic, control dengue fever and dengue hemorrhagic fever).
EGAS00001002276
|
EGA
Cite
GWAS data (Illumina 2.5 M SNPs) in Cuban cohorts of dengue disease
Data Access Committee EGAC00001000601
EGAC00001000601
|
EGA
Cite
Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
Not available
S-EPMC6534876
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets